Latest news about Dr Reddys Laboratories
Dr Reddys Laboratories
1,166.30
-16.50(-1.39%)
Company Performance:
View Company Insights1D-1.39%
1M-9.64%
6M-4.21%
1Y-5.94%
5Y+8.30%
More news about Dr Reddys Laboratories
02Jul 26
Dr Reddy's Laboratories Ltd schedules 42nd AGM for July 23
Dr Reddy's Laboratories Ltd has scheduled its 42nd AGM for July 23, 2026, via video conferencing, recommending a final dividend of ₹8 per share for FY26. The meeting includes the adoption of audited financial statements, auditor appointments, and director re-appointments. E-voting runs from July 19 to July 22, with a record date of July 10, 2026.
01Jul 26
Dr Reddy's targets net zero by FY2045, eliminates coal use
Dr Reddy's Laboratories filed its Business Responsibility and Sustainability Report for FY26, reporting a standalone turnover of ₹20,102 crore and eliminating coal from its fuel mix. The company committed to net zero emissions by FY2045 and carbon neutrality by 2030, with exports contributing 68% of turnover.
21Jun 26
Dr Reddy's fixes July 23 for AGM, recommends Rs 8 dividend
Dr Reddy's Laboratories has scheduled its 42nd Annual General Meeting for July 23, 2026, via video conference, recommending a final dividend of Rs 8 per share for FY26. The record date for dividend entitlement is July 10, 2026. The company detailed TDS regulations, requiring shareholders to submit necessary documents by June 30, 2026, to ensure correct tax deduction.
15Jun 26
Dr Reddy's launches Bosutinib 400mg in US, secures exclusivity
Dr Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, securing 180 days of exclusivity. The product, developed with MSN Laboratories, targets the Tyrosine Kinase Inhibitor category within oncology. The reference brand recorded U.S. sales of approximately $253.8 million for the 12 months ended April 2026.
13Jun 26
Dr Reddys promoters report no share encumbrance in FY26
Dr Reddys Laboratories disclosed that its promoters and persons acting in concert did not create any encumbrance on the company's shares during FY26. The declaration was submitted to the stock exchanges pursuant to SEBI regulations.
11Jun 26
Dr. Reddy's management to meet investors in London on June 16-17
Dr. Reddy's Laboratories Limited announced that its management will participate in analyst and institutional investor meetings in London on June 16 and June 17, 2026. Organized by Investec, these in-person group meetings are part of the company's investor relations activities under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule is subject to change based on exigencies.
04Jun 26
Dr. Reddy's management to meet investors on June 9-10
Dr. Reddy's Laboratories Limited has scheduled meetings with analysts and institutional investors on June 9 and June 10, 2026, in Mumbai and Hyderabad respectively, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
02Jun 26
Dr. Reddy's management to meet Bank of America on June 5
Dr. Reddy's Laboratories Limited announced a regulatory filing on June 1, 2026, regarding a scheduled investor meeting. The management will participate in an in-person group meet organized by Bank of America on June 5, 2026, in Hyderabad between 08:00 and 09:00 IST. The schedule is subject to change due to exigencies.
31May 26
Dr. Reddy's Laboratories files Form 20-F annual report for FY26
Dr. Reddy's Laboratories filed its Annual Report in Form 20-F for the fiscal year ended March 31, 2026, with the United States Securities and Exchange Commission on May 30, 2026. The filing includes annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS). The submission was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
29May 26
Dr. Reddy's rings NYSE bell to celebrate 25 years of listing
Dr. Reddy's Laboratories celebrated 25 years of its NYSE listing by ringing the Closing Bell on May 29, 2026. The ceremony, attended by senior leadership including Chairman Satish Reddy, highlighted the company's governance and innovation. The firm was the first Asian pharmaceutical company, outside Japan, to list on the NYSE in 2001.
28May 26
Dr. Reddy's Laboratories publishes notice on unclaimed dividend transfer
Dr. Reddy's Laboratories Ltd announced the transfer of unclaimed dividends and shares to the IEPF via a notice published on May 27, 2026. The notice appeared in Business Standard and Nava Telangana, following Section 124(6) of the Companies Act, 2013.
28May 26
Dr. Reddy's Laboratories confirms full compliance in FY26 audit
Dr. Reddy's Laboratories Limited reported full compliance with SEBI regulations for FY26 following an audit by M/s. Makarand M. Joshi & Co. The report confirmed no deviations, fines, or regulatory actions against the company.
25May 26
Dr. Reddy's Laboratories Records ₹195.39 Crore Block Trade on NSE at ₹1335.70 Per Share
Dr. Reddy's Laboratories recorded a block trade on the National Stock Exchange involving approximately 1,462,824 shares at ₹1335.70 per share, with the total deal valued at ₹195.39 crores. Such large-scale block trades are typically executed by institutional investors including mutual funds and foreign portfolio investors to facilitate bulk share transfers while minimizing market impact.
21May 26
Dr. Reddy's Expands Semaglutide Portfolio With Oral Biosimilar Launch in India and Generic Injection in Canada
Dr. Reddy's Laboratories has expanded its Semaglutide portfolio with the launch of an oral Semaglutide biosimilar for Type 2 diabetes in India and a generic Semaglutide Injection in Canada, the first G7 country to grant such authorization. The Canadian product, available in 2 mg/pen and 4 mg/pen strengths, received Health Canada's NOC on April 28, 2026, and was launched on May 15, 2026, complementing the company's injectable Obeda® brand already available in India.
19May 26
Dr Reddy's Q4FY26 Net Profit Plunges 86% to ₹220 Cr on One-Time Charges
Dr Reddy's Laboratories reported an 86% decline in Q4FY26 net profit to ₹220 Cr, with revenue falling 12% to ₹7,516 Cr, impacted by a ₹453 Cr shelf stock adjustment, ₹114 Cr VAT provision, and ₹228 Cr impairment charges. FY26 full-year revenues stood at ₹33,593 Cr, up 3% YoY, while PAT declined 24% to ₹4,285 Cr. The company filed its Q4FY26 earnings call transcript with stock exchanges on May 18, 2026, under Regulation 30 of SEBI's listing regulations.
16May 26
Dr. Reddy's Schedules Investor Meets in May-June
Dr. Reddy's Laboratories Limited has announced a new series of analyst and institutional investor meetings scheduled from May 20 to June 3, 2026. The meetings will be held in-person across Hong Kong, Singapore, Toronto, Boston, New York, and Princeton, organized by Elara Capital, Bank of America, Nomura, and Investec. The company stated that the schedule is subject to change due to exigencies.
13May 26
Dr. Reddy's Laboratories Records ₹51.46 Crore Block Trade on NSE
Dr. Reddy's Laboratories recorded a block trade on the NSE involving approximately 407,964 shares at ₹1261.30 per share. The total transaction value amounted to ₹51.46 crores. Block trades of this magnitude are typically associated with institutional investor activity and are monitored closely by market participants for insights into large-scale portfolio movements.
13May 26
Dr. Reddy's Laboratories Board Approves Director Appointments, Auditor Changes, and Senior Management Elevation
Dr. Reddy's Laboratories board meeting on May 12, 2026 approved key governance decisions including re-appointment of Dr. K P Krishnan as Independent Director for a second five-year term, appointment of Mr. Srikanth Velamakanni as Independent Director, appointment of M/s Deloitte Haskins & Sells LLP as Statutory Auditors, re-appointment of M/s Sagar & Associates as Cost Auditors for FY2026-27, and elevation of Mr. Sandeep Khandelwal as Senior Management Personnel. Under Khandelwal's leadership, Dr. Reddy's India topline grew from Rs 2,300 crore to Rs 7,000 crore with EBITDA margins expanding from 19 percent to 24 percent.
30Apr 26
Morgan Stanley Maintains Equal-weight Rating on Dr. Reddy's with ₹1,259 Target Price
Morgan Stanley has assigned an Equal-weight rating to Dr. Reddy's Laboratories with a target price of ₹1,259, citing the company's Health Canada approval for its first generic semaglutide. The approval strengthens the pharmaceutical company's GLP-1 and complex generics portfolio with an estimated revenue potential of approximately $200mn by FY27. However, the brokerage maintains a balanced outlook due to the current valuation of approximately 18x FY28E PE, suggesting the positive regulatory development is already reflected in the stock price.
29Apr 26
Dr Reddy's Receives Notice of Compliance from Health Canada for Semaglutide
Dr Reddy's Laboratories has achieved a regulatory milestone by receiving Notice of Compliance from Health Canada for its generic Semaglutide injection, making it the first company to obtain marketing authorization for this diabetes medication in Canada. The approval covers 2 mg/pen and 4 mg/pen formulations and authorizes immediate commercialization, sale, and distribution across Canada, positioning the company to serve the significant Canadian diabetes market.
29Apr 26
Delhi High Court Issues Warning to Dr. Reddy's Laboratories Over 'Olymviq' Trademark Compliance
Delhi High Court has warned Dr. Reddy's Laboratories over trademark compliance issues related to its weight-loss drug. The court has asked the Hyderabad-based company to file a fresh undertaking detailing compliance status since the 30 March order, which directed discontinuation of the 'Olymviq' name and transition to 'Olymra' for the weight-loss drug. This development highlights ongoing legal challenges the pharmaceutical company must address to satisfy court requirements.
25Apr 26
Dr. Reddy's Laboratories Announces Q4FY26 Results Release on May 12, 2026
Dr. Reddy's Laboratories has submitted a formal regulatory filing announcing the release of Q4 and full year FY26 financial results on May 12, 2026, following a Board Meeting. The company has established a comprehensive communication plan including earnings call at 19:30 PM IST with pre-registration facility and designated investor relations contacts for stakeholder engagement.
16Apr 26
Dr. Reddy's Laboratories Board to Consider Final Dividend for FY 2025-26
Dr. Reddy's Laboratories has announced that its Board of Directors will consider a final dividend proposal for FY 2025-26. The intimation, issued on April 16, 2026, follows an earlier communication from March 23, 2026, and complies with SEBI listing regulations. The pharmaceutical company has not disclosed specific dividend details, maintaining standard corporate governance practices in its communication to multiple stock exchanges.
16Apr 26
BofA Raises Dr. Reddy's Laboratories Target Price to ₹1,540, Maintains Buy Rating
Bank of America has raised Dr. Reddy's Laboratories' target price to ₹1,540 from ₹1,480 while maintaining its Buy rating. The brokerage cited diversified earnings drivers beyond semaglutide, with semaglutide serving as a key growth catalyst. BofA noted the company's resilience against geopolitical risks and highlighted cost-reduction measures that should keep margins above 20% even during revenue delays.
16Apr 26
Dr. Reddy's Laboratories Receives Regulatory Approval for Generic Oral Semaglutide Launch
Dr. Reddy's Laboratories has obtained regulatory approval to launch generic oral semaglutide, allowing the company to produce and distribute three drug formulations. This approval represents a strategic expansion of the company's diabetes treatment portfolio and positions it to compete in the oral semaglutide market with multiple formulation options.
15Apr 26
Citi Maintains Sell Rating on Dr. Reddy's Laboratories with ₹1,070 Target Price Following Brazil ANVISA Rejection
Citi has maintained its Sell rating on Dr. Reddy's Laboratories with a ₹1,070 target price following Brazil ANVISA's rejection of the company's Semaglutide generic Embeltah. The regulatory setback limits early launch participation opportunities amid 16 competing filings in the market. Additionally, Apotex's US tentative approval may provide competitive advantages over Dr. Reddy's in the Canadian market, further impacting the company's positioning in the diabetes medication segment.
14Apr 26
Dr. Reddy's Russian Subsidiary Receives Reduced Tax Penalty of RUB 9.27 Million
Dr. Reddy's Laboratories' Russian subsidiary has received a final tax penalty of RUB 9.27 million (INR 11.40 million) from Russian tax authorities on April 13, 2026, related to VAT levy on marketing services. The penalty represents a significant reduction from the original assessment of RUB 20.09 million (INR 24.50 million). The company has determined that this penalty will have no material impact on its financial operations or activities.
08Apr 26
Dr. Reddy's Laboratories Submits Q4 FY26 SEBI Compliance Certificate for Dematerialization Process
Dr. Reddy's Laboratories filed its Q4 FY26 compliance certificate under SEBI Regulation 74(5) on April 8, 2026, covering the quarter ended March 31, 2026. The certificate, confirmed by registrar Bigshare Services Private Limited, validates that all securities dematerialization processes were completed within regulatory timelines. The filing demonstrates the company's adherence to SEBI depositories regulations and maintains transparency in securities management processes.
08Apr 26
Morgan Stanley Cuts Dr. Reddy's Target Price to ₹1,259 Amid Earnings Downgrades and North America Revenue Decline
Morgan Stanley maintains Equal Weight rating on Dr. Reddy's Laboratories while cutting target price to ₹1,259 from ₹1,285. The brokerage implemented earnings downgrades with FY26 EPS cut 10.7% and 5-6% reductions for FY27-28. North America revenue faces 21% decline in FY26 due to gRevlimid phase-out and GLP-1 uncertainty, though margins expected at 21-22.6% with recovery from FY28 led by semaglutide and biosimilars.
08Apr 26
Dr. Reddy's Laboratories Divests Wholly Owned Subsidiary Svaas Wellness for ₹2.23 Crore
Dr. Reddy's Laboratories has divested its wholly owned subsidiary Svaas Wellness Limited for ₹2.23 crore to Enspirited Technology Services Private Limited. The transaction was completed on April 7, 2026. Svaas Wellness contributed ₹28.5 crore turnover in FY 2025, representing 0.09% of consolidated turnover. The buyer is not affiliated with promoter groups, making it an arm's length transaction.
26Mar 26
Dr. Reddy's Laboratories Allots 3,675 Equity Shares Under Employee Stock Option Plan
Dr. Reddy's Laboratories allotted 3,675 equity shares on March 26, 2026, to eligible employees under its ADR Stock Options Scheme, 2007. The shares were issued at two different exercise prices - 575 shares at Re.1/- each and 3,100 shares at Rs. 735.80/- each. Following this allotment, the company's total issued shares increased to 83,46,57,970 with corresponding share capital of Rs. 83,46,57,970/-. The newly allotted shares rank pari passu with existing shares and comply with SEBI regulations.
25Mar 26
Delhi High Court Orders Dr Reddy's Laboratories to Stop Selling Olympiq Product
Delhi High Court has ordered Dr Reddy's Laboratories to stop selling its Olympiq product, as reported by NDTV Profit. The court directive represents a significant regulatory action that could impact the company's product availability and highlights potential legal or compliance challenges facing the pharmaceutical company.
25Mar 26
Dr. Reddy's Laboratories Amends Fair Disclosure Code for Price Sensitive Information
Dr. Reddy's Laboratories Limited has amended its Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information, approved by the Board on March 24, 2026. The updated code ensures SEBI compliance through comprehensive UPSI handling protocols, designating the Head of Investor Relations as Chief Investor Relations Officer. Key provisions include strict "need to know" information sharing, legitimate purpose frameworks for external disclosures, and mandatory maintenance of structured digital databases with eight-year retention requirements.
23Mar 26
Dr. Reddy's Laboratories Announces Board Meeting on May 12, 2026 for Q4FY26 Results
Dr. Reddy's Laboratories has scheduled a board meeting for May 12, 2026, to review audited financial results for Q4FY26 and FY26, with formal notifications sent to multiple stock exchanges including NSE, BSE, NYSE, and NSE IFSC. The company has implemented a trading window closure from March 25 to May 14, 2026, in compliance with SEBI insider trading regulations.
21Mar 26
Dr. Reddy's Laboratories Launches India's First DCGI-Approved Generic Semaglutide Injection 'Obeda®' for Type 2 Diabetes
Dr. Reddy's Laboratories has officially announced the launch of Obeda®, India's first DCGI-approved generic semaglutide injection for Type 2 diabetes management. The product, developed entirely in-house, demonstrated non-inferior efficacy in Phase III trials with 312 participants and is priced at INR 4,200.00 per month for both 2mg and 4mg strengths. The company plans global expansion and has developed SemaKare™ patient support system alongside metabolic centres of excellence across India.
17Mar 26
Dr. Reddy's Laboratories Receives GST Authority Tax Demand Orders Worth ₹2.20 Crore for FY 2019-22
Dr. Reddy's Laboratories received three GST Authority orders demanding penalties totaling ₹2,20,03,734 for FY 2019-20 to FY 2021-22, with the largest penalty of ₹2,19,48,944 for FY 2019-20. The orders were issued under section 74 of the TNGST Act, 2017, primarily on grounds that certain supplies are taxable in nature. The company has assessed no material impact on its operations and plans to evaluate filing appeals with the appellate authority.
13Mar 26
Dr. Reddy's Partner Immunet Discontinues TACTI-004 Phase III Trial for Eftilagimod Alfa Following Safety Review
Dr. Reddy's Laboratories disclosed that partner Immunet has discontinued the TACTI-004 Phase III trial for Eftilagimod Alfa in lung cancer following an Independent Data Monitoring Committee recommendation based on interim futility analysis. The strategic collaboration, announced in December 2025, gave Dr. Reddy's exclusive rights outside North America, Europe, Japan, and Greater China. Immunet will conduct an orderly study wind-down while reviewing data to determine next steps for the program.
12Mar 26
Dr. Reddy's Laboratories Announces Special Window for Physical Share Transfer Re-lodgement
Dr. Reddy's Laboratories Ltd. announced a special window for re-lodgement of physical share transfer requests through newspaper advertisements published on March 12, 2026. The advertisements appeared in Business Standard and Nava Telangana in compliance with SEBI Regulation 47. The company notified both NSE and BSE about this initiative through official communication signed by Company Secretary K Randhir Singh.
12Mar 26
Dr. Reddy's Laboratories Allots 10,275 Equity Shares Under Employee Stock Options Scheme
Dr. Reddy's Laboratories Limited allotted 10,275 equity shares of Re. 1/- each to eligible employees on March 12, 2026, under its Employee Stock Options Schemes from 2002 and 2007. The allotment increased the company's total issued shares to 83,46,54,295 and total issued share capital to Rs. 83,46,54,295/-. The newly issued shares rank pari passu with existing shares and carry no lock-in restrictions.
10Mar 26
Dr. Reddy's Laboratories Elevates M S Madhu Sundar as Global Head of Quality and PV
Dr. Reddy's Laboratories has elevated M S Madhu Sundar as Global Head of Quality and PV, effective April 1, 2026. The Board approved this appointment based on committee recommendations, with Madhu Sundar transitioning from his current role as Head Global Manufacturing FTO Oral Solid Dosages & Operational Excellence. He will also join as Senior Management Personnel and Member of Management Council. The company announced additional role changes for other senior management personnel including M V Ramana as CEO Global Generics and Sanjay Sharma as Chief Operating Officer.
06Mar 26
Dr. Reddy's Laboratories Receives USFDA VAI Classification for Srikakulam Facility
Dr. Reddy's Laboratories has successfully completed the USFDA regulatory review process for its formulations manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA classified the inspection outcome as Voluntary Action Indicated (VAI) and officially closed the inspection, allowing the facility to continue operations while addressing any identified concerns voluntarily.
26Feb 26
Dr Reddy's Semaglutide Launch Timeline Faces Potential Delays in Canada
Dam Capital has flagged potential delays in Dr Reddy's Laboratories' semaglutide launch in Canada, with Sandoz projecting a H2 CY26 timeline instead of the earlier H1 CY26 guidance. The regulatory approvals for both Brazil and Canada markets may face delays, potentially impacting the pharmaceutical company's international expansion strategy and market entry plans for the diabetes medication.
25Feb 26
Dr. Reddy's Laboratories Receives SEC Letter Concluding Investigation Without Enforcement Action
Dr. Reddy's Laboratories has successfully concluded a multi-year SEC investigation that began with anonymous complaints in November 2020 regarding alleged improper payments to healthcare professionals in Ukraine and other countries. The company maintained full cooperation throughout the process and received official communication on February 23, 2026, confirming the SEC's decision not to recommend any enforcement action at this time.
17Feb 26
Dr. Reddy's Laboratories Allots 12,665 Equity Shares Under Employee Stock Option Schemes
Dr. Reddy's Laboratories allotted 12,665 equity shares to employees on February 17, 2026, under two employee stock option schemes from 2002 and 2007. The shares were exercised at three different price points, with the highest at Rs. 735.80/- per share. This allotment increased the company's total issued shares to 83,46,44,020, with corresponding share capital of Rs. 83,46,44,020/-. The newly issued shares rank equally with existing shares and are immediately tradeable across all exchanges where the company is listed.
24Jan 26
Dr. Reddy's Russian Subsidiary Receives Tax Audit Decision with INR 24.50 Million Penalty
Dr. Reddy's Laboratories disclosed that its Russian subsidiary received a tax audit decision on January 23, 2026, from Russian tax authorities, resulting in a penalty of Rub 20.09 million (INR 24.50 million) for VAT levy on reclassified marketing services. The company stated there is no material impact on its financials or operations and will evaluate filing a response to the tax authority.
21Jan 26
Dr. Reddy's Laboratories Reports Q3FY26 Results with 4.4% Revenue Growth
Dr. Reddy's Laboratories reported Q3FY26 consolidated revenues of ₹87,268 million, up 4.4% YoY, with net profit of ₹12,098 million. Growth was driven by branded businesses and favorable forex, offsetting lower Lenalidomide sales. The company achieved several strategic milestones including collaboration with Immutep and launch of Hevaxin® vaccine, while managing the impact of India's New Labour Codes implementation.
08Jan 26
Dr Reddy's Labs to Release Q3FY26 Results on January 21 with Earnings Call
Dr Reddy's Laboratories has scheduled its Q3FY26 results announcement for January 21, 2026, covering the quarter ended December 31, 2025. The company will host an earnings call at 19:30 PM IST (9:00 AM ET) following the board meeting, with comprehensive stakeholder access through multiple channels including website presentations and call transcripts.
01Jan 26
Dr. Reddy's Laboratories Receives GST Orders Worth ₹8.38 Crores in Penalties for FY 2018-19 to FY 2022-23
Dr. Reddy's Laboratories disclosed receiving five GST orders from Visakhapatnam authority imposing total penalties of ₹8.38 crores for FY 2018-19 to FY 2022-23. The orders, received on December 31, 2025, allege excess input tax credit claims under APGST Act 2017. The company states no material impact on operations and plans to evaluate filing an appeal.
01Jan 26
Dr. Reddy's Swiss Arm Gets USFDA Complete Response Letter For AVT03 Biosimilar
Dr. Reddy's Laboratories announced that its Swiss subsidiary received a Complete Response Letter from USFDA for the AVT03 biosimilar application, which is a proposed denosumab biosimilar to Prolia and Xgeva. The regulatory setback stems from observations during a pre-license inspection of manufacturing partner Alvotech's facility in Reykjavik, highlighting compliance issues that need to be addressed before approval.
15Dec 25
Dr. Reddy's Receives USFDA Form 483 for Srikakulam Plant with Five Observations
The US Food and Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) at Dr Reddy's Laboratories' Srikakulam plant. The regulatory body issued a Form 483 citing five specific concerns observed during the inspection. Form 483 indicates potential violations of food and drug laws and regulations. Dr Reddy's is required to respond with corrective actions within 15 working days to address these concerns and maintain compliance with US regulatory standards.
12Dec 25
High Court Refuses to Stay Dr Reddy's Export of Semaglutide to International Markets
A High Court bench has declined to issue a stay order against Dr Reddy's Laboratories' export of semaglutide to certain international markets. This decision allows the pharmaceutical company to continue its overseas sales of the important diabetes and weight management medication, maintaining its supply chain and commercial commitments internationally.
12Dec 25
Dr. Reddy's Sets Science-Based Net Zero Targets by 2045
Dr Reddy's Laboratories has announced science-based Net Zero climate targets, aiming to achieve zero greenhouse gas emissions across its value chain by FY2045. The company has set near-term and long-term goals, including an 80% reduction in Scope 1 & 2 emissions and a 51.6% reduction in Scope 3 emissions per INR value added by FY2030. Dr Reddy's plans to be coal-and furnace oil-free by FY26 and source 68% of its power from renewable energy by FY25. This commitment makes Dr Reddy's the first Indian pharmaceutical company to set such ambitious climate targets.
11Dec 25
Dr. Reddy's Laboratories Records ₹32.40 Crore NSE Block Trade at ₹1,251.50 Per Share
Dr. Reddy's Laboratories recorded a significant NSE block trade worth ₹32.40 crores involving 258,904 shares at ₹1,251.50 per share. The transaction reflects substantial institutional activity and strategic investment decisions in the pharmaceutical major. Such block trades typically indicate meaningful capital deployment by institutional investors and can influence trading dynamics.
03Dec 25
Dr. Reddy's Laboratories Sees Rs. 113.93 Crore Block Trade on NSE
A significant block trade of 888,017 shares of Dr Reddy's Laboratories was executed on the National Stock Exchange (NSE) at Rs. 1,283.00 per share. The total transaction value amounted to Rs. 113.93 crores. This large-volume trade indicates substantial institutional or bulk investor activity in the pharmaceutical company's stock.
11Nov 25
Dr. Reddy's Laboratories Thwarts Cyber Fraud Attempt, Confirms No Financial Loss
Dr Reddy's Laboratories successfully prevented a cyber fraud attempt involving vendor email impersonation. The hackers tried to redirect a legitimate payment of approximately Rs 2.16 crore. The company's internal teams and banking partners detected the fraud early, implemented preventive measures, and froze the funds promptly. No financial loss occurred to the company or the vendor. The incident was not categorized as material under SEBI regulations, and thus did not require formal disclosure.
10Nov 25
Dr. Reddy's Global Head of Biologics Jayanth Sridhar to Step Down
Jayanth Sridhar, Global Head of Biologics at Dr Reddy's Laboratories, has resigned to pursue opportunities outside the company. His resignation is effective January 31, 2026, with a transition period until then. The company has notified stock exchanges as per SEBI regulations. No immediate information on a successor or impacts on the biologics division has been provided.
09Nov 25
Dr. Reddy's Laboratories Falls Victim to Rs 2.16 Crore Email Fraud
Dr Reddy's Laboratories lost Rs 2.16 crore in a sophisticated cyber fraud scheme. Fraudsters used email spoofing to impersonate executives from Group Pharmaceutical Ltd and divert a payment. The scam involved creating a fake email address similar to the legitimate one, differing only in capitalization. Group Pharmaceutical Ltd has filed an FIR with Bengaluru City Cyber Crime Police. The case is registered under IT Act sections for identity theft and cheating by personation. The accused's location has been traced to Vadodara, Gujarat.
01Nov 25
Dr Reddy's Stock Dips 4% Following Health Canada's Non-Compliance Notice for Semaglutide Generic
Dr Reddy's Laboratories experienced a 4% decline in share price following a notice of non-compliance from Health Canada for its Abbreviated New Drug Application (ANDA) for Semaglutide, a weight management medication. The setback impacts the company's significant investments in infrastructure for Semaglutide and its plans to be a market leader. This incident is part of a broader trend of regulatory challenges faced by Indian pharmaceutical companies in complex drug applications.
30Oct 25
Dr. Reddy's Q2 Revenue Grows 9.8% Despite Lenalidomide Pressure; EBITDA Margin at 26.7%
Dr Reddy's Laboratories reported Q2 consolidated revenues of ₹8,805 crores ($992 million), up 9.8% year-over-year. Profit After Tax increased by 14% YoY to ₹1,437 crores ($162 million). North America Generics revenue declined 16% YoY due to price erosion in key products, while European Generics revenue grew 115% YoY. India business revenue increased 13% YoY, and Emerging Markets revenue rose 14% YoY. The company launched new products across markets, acquired Stugeron® brand, and made progress in biosimilars and novel drugs development. Dr Reddy's maintains focus on growth strategies despite challenges in the US generics market.
29Oct 25
Dr Reddy's Faces Regulatory Hurdle in Canada for Semaglutide Submission
Dr Reddy's Laboratories received a Notice of Non-Compliance from Canadian regulators regarding its Abbreviated New Drug Submission for Semaglutide Injection. The notice requests additional information and clarifications. Dr Reddy's plans to respond within the stipulated time frame and remains confident in their product's quality and safety. This setback could delay the company's entry into the Canadian market with its semaglutide product, a medication used for diabetes management and weight loss.
27Oct 25
Dr. Reddy's Q2 Profit Rises to ₹1,347 Crore, Outlines Future Financial Targets
Dr Reddy's Laboratories reported a 7.33% year-over-year increase in net profit to ₹1,347.00 crore for Q2 FY24, surpassing market estimates. Revenue grew by 9.94% to ₹8,828.00 crore. However, EBITDA declined slightly to ₹2,000.00 crore, with margins compressing to 22.77%. The company projects SG&A costs at 28-30% of sales, R&D expenses around 7%, and aims for 25% EBITDA margins by FY27. Dr Reddy's plans to secure Semaglutide approvals in 87 countries within 12-15 months and expects 20-25% gross margins in pharmaceutical services and active ingredients.
24Oct 25
Dr. Reddy's Clarifies No Partnership with Eli Lilly for Tirzepatide, Projects Growth Through Biosimilars and Global Expansion
Dr Reddy's Laboratories has officially stated it has no plans to collaborate with Eli Lilly for launching Tirzepatide, a diabetes medication, in India. The company expects continued growth driven by its biosimilars portfolio, API pipeline, and global expansion strategy. Dr Reddy's reported a 22% return on capital employed and anticipates growth from Europe and emerging markets, with high-margin products expected to enhance long-term profitability.
24Oct 25
Dr. Reddy's Q2FY26: Revenue Grows 9.8% YoY, Profit Up 14% Despite Challenges
Dr Reddy's Laboratories reported a 9.8% YoY revenue growth to ₹8,805.00 crore and a 14% increase in profit to ₹1,437.00 crore in Q2FY26. Global Generics revenue grew 10% YoY, with strong performance in Europe (+138% YoY) offsetting a 13% decline in North America. PSAI segment revenue increased 12% YoY. The company faced challenges with gross margin declining 492 bps YoY due to reduced Lenalidomide sales and price erosion in North America. Key developments include the acquisition of the STUGERON® portfolio and launches of novel drugs in India.
23Oct 25
Dr Reddy's Q2 Results Preview: Analysts Project 11-18% PAT Growth Despite US Challenges
Dr Reddy's Laboratories is set to announce Q2 FY24 results on October 24. Analysts project steady performance with 11-18% YoY PAT growth and 10-14% YoY revenue growth. Strong performance in India and Europe is expected to offset US market challenges. EBITDA margins may face slight compression due to pricing pressures in the US and product mix changes. The company's diversified geographical presence is seen as a buffer against market-specific challenges.
23Oct 25
Dr. Reddy's Srikakulam Facility Receives FDA Inspection Report with Voluntary Action Indicated Status
Dr Reddy's Laboratories' Srikakulam facility has received a 'voluntary action indicated' (VAI) status in the USFDA's establishment inspection report. This outcome allows the facility to continue operations without immediate regulatory intervention, though some voluntary actions may be needed to address minor issues. The VAI status is generally viewed positively, potentially boosting investor confidence and demonstrating the company's ability to meet stringent regulatory standards.
21Oct 25
Dr. Reddy's Srikakulam Facility Receives 'Voluntary Action Indicated' Classification from USFDA
Dr Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the USFDA for its formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh. The inspection, conducted on July 18, 2025, has been classified as 'Voluntary Action Indicated (VAI)' and officially closed. This classification allows the company to address minor concerns voluntarily without further regulatory intervention. The company disclosed this development to stock exchanges in compliance with SEBI regulations.
12Oct 25
Dr. Reddy's and Zydus Recall Pharmaceutical Products in US Market
Dr. Reddy's Laboratories is recalling 571 vials of Succinylcholine Chloride Injection due to out-of-specification results in stability testing. Zydus Pharmaceuticals is recalling over 1,500 boxes of Entecavir tablets (912 bottles of 0.5mg and 600 bottles of 1mg) due to failed impurity/degradation specifications. Both recalls are classified as Class II by the FDA, indicating potential temporary or medically reversible health consequences.
24Sept 25
Dr Reddy's to Offer Generic HIV Prevention Drug at $40 Annually by 2027
Dr Reddy's Laboratories and Hetero Labs are set to introduce generic versions of lenacapavir, a revolutionary HIV prevention drug, priced at approximately $40 per year. Distribution is scheduled to begin in 2027. The companies received royalty-free licenses from Gilead Sciences to manufacture and distribute the drug in 120 low- and lower-middle-income countries. The original drug, marketed as Yeztugo by Gilead Sciences, costs around $28,000 annually in the US. This initiative, supported by global health organizations, could potentially benefit millions in low-income countries and significantly impact global HIV prevention efforts.
22Sept 25
Dr. Reddy's Secures Positive CHMP Opinion for Denosumab Biosimilar AVT03
Dr Reddy's Laboratories has received a positive opinion from the EMA's CHMP for AVT03, a proposed biosimilar of denosumab. AVT03 is a biosimilar candidate to Prolia® and Xgeva®. Upon approval, it will be marketed as Acvybra® and Xbonzy®. The company plans to commercialize AVT03 in Europe and the UK, with Alvotech handling development and manufacturing. This advancement expands Dr Reddy's biosimilar portfolio, potentially increasing access to osteoporosis treatment and offering cost savings to healthcare systems.
18Sept 25
Dr. Reddy's Promoters Transfer 20.58% Stake to Family Trusts for Succession Planning
Dr Reddy's Laboratories' promoters, Satish Reddy Kallam and G V Prasad, transferred a combined 20.58% stake to their respective family trusts on September 17, 2025. Satish Reddy Kallam transferred 9.06% to VSD Family Trust, reducing his stake from 10.27% to 1.21%. G V Prasad transferred 11.51% to GVP Family Trust, reducing his stake to 0%. The transfer, involving 17,17,26,540 equity shares, was part of a succession planning initiative. Despite individual changes, the aggregate promoter group holding remains at 26.64%. The transfer was conducted under a SEBI exemption for succession planning purposes.
17Sept 25
Dr. Reddy's Prepares for Generic Weight-Loss Drug Ingredients and Launches Novel Molecule Tegoprazan
Dr Reddy's Laboratories is preparing to supply ingredients for generic versions of popular weight-loss medications. The company has also launched Tegoprazan, a novel molecule for acid-related gastrointestinal diseases, in India under the brand name PCAB®. Tegoprazan showed 99% efficacy in treating GERD patients during clinical trials. The drug is approved in 21 countries and is under registration in several others. This dual focus demonstrates Dr Reddy's commitment to addressing diverse healthcare needs in the pharmaceutical industry.
16Sept 25
Dr. Reddy's Launches Novel Acid Blocker Tegoprazan in India Under Brand PCAB
Dr Reddy's Laboratories has introduced Tegoprazan, a next-generation potassium-competitive acid blocker (P-CAB), in India under the brand name PCAB®. The drug is designed to treat acid-related gastrointestinal diseases, including GERD and gastric ulcers. In clinical trials, 99% of GERD patients achieved endoscopic healing by Week 8. Tegoprazan is already approved in 21 countries and aims to address the needs of approximately 38% of the Indian population affected by acid peptic diseases. This launch is part of Dr Reddy's exclusive partnership with South Korea's HK inno.N Corporation.
15Sept 25
Dr Reddy's Laboratories Receives FDA Form 483 with Five Observations at Bachupally Biologics Facility
The US FDA issued a Form 483 with five observations following a Pre-Approval Inspection at Dr Reddy's Laboratories' Bachupally biologics facility. The company will need to address these observations, which could potentially impact product approvals and operations. Dr Reddy's is expected to develop a corrective action plan and respond to the FDA's concerns promptly.
13Sept 25
Dr. Reddy's Receives Form 483 with Five Observations Following USFDA Inspection at Hyderabad Biologics Facility
Dr Reddy's Laboratories' biologics manufacturing facility in Bachupally, Hyderabad underwent a USFDA Pre-Approval Inspection from September 4-12. The inspection resulted in a Form 483 with five observations, which the company has committed to address within the stipulated timeline. This inspection follows a previous one in October 2023. Separately, Dr Reddy's acquired Janssen's Stugeron portfolio for $50.50 million, covering 18 markets across Asia-Pacific and EMEA regions. The company reported strong Q1 financial results with revenue at ₹8,542.00 crore and net profit at ₹1,417.80 crore.
11Sept 25
Dr. Reddy's Expands CNS Portfolio with $50.5 Million Acquisition of Stugeron Brand
Dr Reddy's Laboratories has acquired the Stugeron brand and associated products from Janssen Pharmaceutica NV for $50.5 million. The deal covers 18 markets across APAC and EMEA regions, with India and Vietnam as key markets. Stugeron, an antihistamine used for treating vestibular disturbances and vertigo, holds a leading position in India's anti-vertigo market. This acquisition allows Dr Reddy's to enter the anti-vertigo segment and strengthen its CNS portfolio. The company plans to leverage its market access to expand Stugeron's reach, aligning with its goal of reaching over 1.5 billion patients by 2030. Dr Reddy's shares closed 0.87% higher following the announcement.
05Sept 25
Dr. Reddy's Reports 13% Revenue Growth in FY20, Declares Rs. 25 Final Dividend
Dr Reddy's Laboratories announced consolidated revenues of Rs. 17,460.00 crore for FY20, a 13% year-over-year growth. The Global Generics segment contributed Rs. 13,810.00 crore, growing 12%. North America Generics revenue reached Rs. 6,470.00 crore, up 8%, while India operations generated Rs. 2,890.00 crore, up 11%. Profit after tax was Rs. 1,950.00 crore. The company recommended a final dividend of Rs. 25.00 per equity share. An impairment charge of Rs. 1,680.00 crore was recorded. All facilities previously under FDA warning now have 'Voluntary Action Indicated' status.
03Sept 25
Dr Reddy's Laboratories May Benefit from Potential GST Exclusion on Cancer Medications
Dr Reddy's Laboratories could potentially benefit from a proposed change in the GST structure that might exclude cancer medications. This could lead to lower pricing of cancer drugs, improved market accessibility, and enhanced value of the company's oncology portfolio. The move could allow Dr Reddy's to adjust its pricing strategy and potentially reach a broader patient base. However, the benefits are contingent on the final decision regarding the GST exclusion for cancer medications.
28Aug 25
Dr Reddy's Secures Court Stay on Tax Reassessment, Cipla Recalls Asthma Medication in US
Dr Reddy's Laboratories secured an interim stay on income tax reassessment proceedings related to a merger, halting a potential ₹2,395.00 crore demand. Cipla is recalling over 20,000 packs of Ibuterol Sulfate Inhalation Aerosol in the US. Biocon Pharma received FDA tentative approval for Sitagliptin Tablets USP in three strengths for type 2 diabetes treatment.
26Aug 25
Dr. Reddy's Secures Interim Stay on Tax Reassessment, Expresses Optimism on GST Reforms
Dr Reddy's Laboratories has obtained an interim stay from the Telangana High Court on income tax reassessment proceedings related to its merger with Dr. Reddy's Holding Limited. The stay applies to both the order under Section 148A(3) and the reassessment notice under Section 148 of the Income-tax Act. Dr Reddy's believes there is no tax evasion from the merger and will take appropriate actions as needed. The merger scheme includes an indemnification clause protecting the company from potential liabilities.
08Aug 25
Dr. Reddy's Miryalaguda API Plant Receives USFDA VAI Classification, Inspection Closed
Dr Reddy's Laboratories' Active Pharmaceutical Ingredient (API) manufacturing facility in Miryalaguda, Telangana, has received a 'Voluntary Action Indicated' (VAI) classification from the United States Food and Drug Administration (USFDA) following an inspection. The company received an Establishment Inspection Report (EIR) from the USFDA, officially closing the inspection under 21 CFR 20.64(d)(3). K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR of Dr. Reddy's, disclosed this development to the stock exchanges.
08Aug 25
Dr Reddys Laboratories Dissolves Wholly Owned Subsidiary Imperial Owners and Land Possessions
Dr Reddy's Laboratories announced the dissolution of its wholly owned subsidiary, Imperial Owners and Land Possessions Private Limited, following a voluntary liquidation process. The National Company Law Tribunal, Hyderabad Bench, approved the dissolution on August 5, 2025. Dr Reddy's stated that the liquidation will not materially impact its consolidated financial statements as Imperial was not a material subsidiary. The company has informed relevant stock exchanges in compliance with SEBI regulations.
29Jul 25
Dr. Reddy's Q1 Revenue Surges 11% YoY, EBITDA Margin at 26.7%
Dr Reddy's Laboratories reported consolidated revenues of ₹8,545.00 crores ($997.00 million) for Q1, up 11% year-over-year. The company achieved an EBITDA margin of 26.7% and profit after tax of ₹1,419.00 crores ($166.00 million). Performance varied across segments, with European Generics showing significant growth while North America Generics declined. Strategic initiatives include a biosimilar collaboration with Alvotech, expansion of the Nicotine Replacement Therapy business, and focus on complex generics and biosimilars. The company maintains a positive outlook, targeting an EBITDA margin of 25% or higher.
25Jul 25
Dr Reddy's Invests ₹565 Crore in Russian Subsidiary, Reports Strong Quarterly Results
Dr Reddy's Laboratories invested ₹565.40 crore for a 45.19% stake in its Russian subsidiary, DRL Russia, to support working capital needs. The company reported Q3 revenue of ₹8,542.00 crore, up from ₹7,672.70 crore year-over-year. Net profit increased to ₹1,417.80 crore from ₹1,392.00 crore, while EBITDA rose to ₹2,287.00 crore from ₹2,160.00 crore. However, EBITDA margin slightly decreased to 26.70% from 28.20%. The company's shares closed at ₹1,277.10, up 0.97%.
25Jul 25
Dr Reddy's Laboratories Invests ₹5.65 Billion in Russian Subsidiary
Dr Reddy's Laboratories has invested ₹5.65 billion (about $75 million) to acquire a 45.19% stake in its step-down wholly-owned subsidiary, Dr Reddy's Laboratories LLC, Russia (DRL Russia). The investment aims to strengthen the company's presence in the Russian market and support DRL Russia's working capital needs. DRL Russia has shown consistent growth, with its turnover increasing from ₹1,915 crore in FY2023 to ₹2,347 crore in FY2025. The investment was approved at the company's 41st Annual General Meeting.
24Jul 25
Dr. Reddy's Shareholders Approve G V Prasad's Re-appointment as Co-Chairman and Managing Director
Dr Reddy's Laboratories held its 41st Annual General Meeting on July 24, 2025. Shareholders approved G V Prasad's re-appointment as Co-Chairman and Managing Director for a five-year term from January 30, 2026, to January 29, 2031. Other key resolutions passed include adoption of financial statements, declaration of Rs. 8.00 dividend per equity share, approval of Cost Auditors' remuneration, and appointment of Secretarial Auditors. The AGM saw strong participation with 85 members attending via video conferencing, representing 22,33,11,552 shares.
24Jul 25
Dr. Reddy's Shares Rise Despite Missing Q1 Profit Estimates; Brokerages Mixed on Outlook
Dr Reddy's Laboratories reported Q2 consolidated net profit of Rs 1,418.00 crore, up 1.8% YoY but below estimates. Revenue rose 11.4% to Rs 8,572.00 crore, missing projections. Operating margins narrowed to 25.4%. The earnings miss was attributed to U.S. generics pricing pressure and lower operating leverage. Despite this, shares traded 2.53% higher. Brokerage reactions were mixed, with ratings ranging from 'Equal-weight' to 'Buy'. The company faces U.S. market headwinds but sees strength in branded markets and its Nicotine Replacement Therapy portfolio.
23Jul 25
Dr. Reddy's Reports 11% Revenue Growth in Q1, Expands Strategic Partnerships
Dr Reddy's Laboratories reported consolidated revenues of ₹85,452.00 million for Q1, an 11% year-over-year increase. Global Generics segment grew 10%, with Europe showing 142% growth. North America revenues declined 11% due to price erosion in key products. India market grew 11%, while PSAI segment increased 7%. The company expanded partnerships with Alvotech and Sanofi, and launched new products. R&D expenses were 7.3% of revenues. Despite challenges in the U.S. generics market, Dr Reddy's remains focused on strengthening its base business through pipeline delivery and productivity improvements.
23Jul 25
Dr. Reddy's Plans Global Expansion with Generic Weight-Loss Drugs
Dr Reddy's Laboratories plans to introduce generic versions of weight-loss medications across 87 countries, including Canada, India, and Brazil, in the coming year. The company aims to capitalize on the growing global demand for these treatments by making them more accessible and affordable. Additionally, Dr Reddy's intends to appoint Deloitte Haskins & Sells LLP as its Statutory Auditors for five years, starting from the financial year 2026-27, subject to approvals.
23Jul 25
Dr. Reddy's Reports 11% Revenue Growth to ₹8,545 Crore in Q1 FY26, Driven by NRT Portfolio and Branded Markets
Dr Reddy's Laboratories reported consolidated revenues of ₹8,545 crore for Q1 FY26, up 11% year-over-year. Global Generics segment grew 10%, with Europe showing 142% growth. North America revenues declined 11% due to price erosion in key products. Profit after Tax increased 2% YoY to ₹1,418 crore. The company expanded partnerships for biosimilars and launched new products in India. Management remains focused on strengthening the base business amid challenges in the U.S. generics market.
22Jul 25
Dr Reddy's Q1 Results Preview: Analysts Expect Revenue Growth Up to 19%, FDA Inspection Concludes Positively
Dr Reddy's Laboratories is set to announce Q1 results on July 23. Analysts project mixed earnings with PAT estimates ranging from ₹1,399.00 crore to ₹1,659.00 crore, and revenue estimates between ₹8,491.00 crore and ₹9,094.00 crore. Growth drivers include steady domestic demand, strong US sales, Nicotinell acquisition, and favorable currency movements. The company received a positive FDA inspection outcome for its API facility in Middleburgh, New York, classified as 'Voluntary Action Indicated'.
21Jul 25
Dr. Reddy's New York API Facility Receives USFDA Approval with VAI Status
Dr Reddy's Laboratories' Active Pharmaceutical Ingredient (API) facility in Middleburgh, New York, has received an Establishment Inspection Report (EIR) from the USFDA with a 'Voluntary Action Indicated' (VAI) status. The inspection is officially closed under 21 CFR 20.64(d)(3). This outcome allows the facility to continue operations without significant regulatory hurdles, indicating ongoing compliance with FDA standards. The company views this as a positive development, reinforcing its position in the global pharmaceutical market.
20Jul 25
Dr Reddy's Andhra Pradesh Plant Receives Seven FDA Observations
Dr Reddy's Laboratories' manufacturing facility in Andhra Pradesh has received seven observations from the U.S. Food and Drug Administration (USFDA) following a recent inspection. These observations, typically issued on Form 483, indicate potential regulatory compliance issues at the facility. The company is expected to respond to the FDA with corrective and preventive actions to address the identified issues. This development may impact Dr Reddy's operations and regulatory standing in the United States, a key pharmaceutical market.
18Jul 25
FDA Inspection of Dr. Reddy's Srikakulam Facility Yields 7 Observations
The USFDA completed an inspection of Dr. Reddy's Laboratories' formulations manufacturing facility in Srikakulam, Andhra Pradesh, from July 10 to July 18, 2025. The inspection, which included both GMP and Pre-Approval assessments, resulted in a Form 483 with seven observations. Dr. Reddy's has committed to addressing these issues within the stipulated timeline. The company's response and ability to resolve these observations will be crucial for maintaining its standing with the USFDA and ensuring continued operations at the Srikakulam facility.
17Jul 25
Dr Reddy's Laboratories Anticipates Positive Q1 Results Despite Revlimid Concerns
Dr Reddy's Laboratories is expected to report positive revenue and profit figures in its Q1 results on July 23, despite concerns about potential revenue decline from its cancer drug Revlimid. The anticipated growth reflects the company's strong market position and diverse product portfolio. The positive outlook suggests successful mitigation of risks associated with any single product line and highlights the company's effective diversification strategy.
12Jun 25
Dr Reddy's Laboratories: Eight Arrested in ₹2 Crore Semaglutide Theft Case
Dr Reddy's Laboratories experienced a significant theft at its Srikakulam warehouse, with 460 grams of Semaglutide, an anti-diabetic drug worth over ₹2 crore, stolen. Eight individuals, including four company employees, were arrested. Police recovered 440 grams of genuine Semaglutide and 460 grams of counterfeit powder. A separate theft of palladium acetate worth ₹60 lakh is also under investigation. The incidents raise concerns about internal security and may lead to a security overhaul, potential financial and reputational impacts, and increased regulatory scrutiny for the company.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind PharmaDr Reddys Laboratories
Aurobindo Pharma
Laurus Labs
1,954.00
(+0.57%)
7,305.00
(-1.10%)
5,065.20
(+0.63%)
1,393.00
(-1.56%)
1,113.80
(-1.11%)
2,396.30
(-0.44%)
2,557.40
(+0.50%)
1,166.30
(-1.39%)
1,523.40
(-0.67%)
1,568.30
(-0.60%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
